
Nonclinical development strategies to optimise your clinical development programme
Being first to market with an innovator drug remains the ultimate goal for all, and most organisations are constantly reviewing ...Read more >
Being first to market with an innovator drug remains the ultimate goal for all, and most organisations are constantly reviewing ...Read more >
February 27, 2023 Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel ...Read more >
The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of ...Read more >
One of the key challenges facing researchers working on treatments for rare diseases is recruitment for clinical trials. Because these ...Read more >
In recent decades, clinical trials and their methodologies have evolved significantly. New technologies have led to improved research methods, techniques ...Read more >
Pharmaceutical companies all over the world outsource some or all elements of their clinical trials in order to better manage ...Read more >
Designing a clinical trial is a complex and challenging process. There are several key factors that researchers have to consider, ...Read more >
Today we celebrate the success of our colleague, and Scientific Advisory Board member, Dr Samson Fung. Dr Fung was recently ...Read more >
Pharmaceutical R&D is the process of developing drugs and pharmaceuticals so they are appropriate and safe for market use. The ...Read more >
Clinical data management (CDM) is one of the most integral processes in any clinical study. Data is at the heart ...Read more >
Amyotrophic lateral sclerosis (ALS) is a rare, progressive neurodegenerative disease that affects the motor neurons controlling voluntary muscle movement. The ...Read more >
We are thrilled that two of our Simbec-Orion colleagues are amongst the Welsh businesses and individuals shortlisted in the Wales ...Read more >